Cargando…

Thirty-One Novel Biomarkers as Predictors for Clinically Incident Diabetes

BACKGROUND: The prevalence of diabetes is increasing in all industrialized countries and its prevention has become a public health priority. However, the predictors of diabetes risk are insufficiently understood. We evaluated, whether 31 novel biomarkers could help to predict the risk of incident di...

Descripción completa

Detalles Bibliográficos
Autores principales: Salomaa, Veikko, Havulinna, Aki, Saarela, Olli, Zeller, Tanja, Jousilahti, Pekka, Jula, Antti, Muenzel, Thomas, Aromaa, Arpo, Evans, Alun, Kuulasmaa, Kari, Blankenberg, Stefan
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2852424/
https://www.ncbi.nlm.nih.gov/pubmed/20396381
http://dx.doi.org/10.1371/journal.pone.0010100
_version_ 1782179942561218560
author Salomaa, Veikko
Havulinna, Aki
Saarela, Olli
Zeller, Tanja
Jousilahti, Pekka
Jula, Antti
Muenzel, Thomas
Aromaa, Arpo
Evans, Alun
Kuulasmaa, Kari
Blankenberg, Stefan
author_facet Salomaa, Veikko
Havulinna, Aki
Saarela, Olli
Zeller, Tanja
Jousilahti, Pekka
Jula, Antti
Muenzel, Thomas
Aromaa, Arpo
Evans, Alun
Kuulasmaa, Kari
Blankenberg, Stefan
author_sort Salomaa, Veikko
collection PubMed
description BACKGROUND: The prevalence of diabetes is increasing in all industrialized countries and its prevention has become a public health priority. However, the predictors of diabetes risk are insufficiently understood. We evaluated, whether 31 novel biomarkers could help to predict the risk of incident diabetes. METHODS AND FINDINGS: The biomarkers were evaluated primarily in the FINRISK97 cohort (n = 7,827; 417 cases of clinically incident diabetes during the follow-up). The findings were replicated in the Health 2000 cohort (n = 4,977; 179 cases of clinically incident diabetes during the follow-up). We used Cox proportional hazards models to calculate the relative risk of diabetes, after adjusting for the classic risk factors, separately for each biomarker. Next, we assessed the discriminatory ability of single biomarkers using receiver operating characteristic curves and C-statistics, integrated discrimination improvement (IDI) and net reclassification improvement (NRI). Finally, we derived a biomarker score in the FINRISK97 cohort and validated it in the Health 2000 cohort. A score consisting of adiponectin, apolipoprotein B, C-reactive protein and ferritin almost doubled the relative risk of diabetes in the validation cohort (HR per one standard deviation increase 1.88, p = 2.8 e-5). It also improved discrimination of the model (IDI = 0.0149, p<0.0001) and reclassification of diabetes risk (NRI = 11.8%, p = 0.006). Gender-specific analyses suggested that the best score differed between men and women. Among men, the best results were obtained with the score of four biomarkers: adiponectin, apolipoprotein B, ferritin and interleukin-1 receptor antagonist, which gave an NRI of 25.4% (p<0.0001). Among women, the best score included adiponectin, apolipoprotein B, C-reactive protein and insulin. It gave an NRI of 13.6% (p = 0.041). CONCLUSIONS: We identified novel biomarkers that were associated with the risk of clinically incident diabetes over and above the classic risk factors. This gives new insights into the pathogenesis of diabetes and may help with targeting prevention and treatment.
format Text
id pubmed-2852424
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-28524242010-04-14 Thirty-One Novel Biomarkers as Predictors for Clinically Incident Diabetes Salomaa, Veikko Havulinna, Aki Saarela, Olli Zeller, Tanja Jousilahti, Pekka Jula, Antti Muenzel, Thomas Aromaa, Arpo Evans, Alun Kuulasmaa, Kari Blankenberg, Stefan PLoS One Research Article BACKGROUND: The prevalence of diabetes is increasing in all industrialized countries and its prevention has become a public health priority. However, the predictors of diabetes risk are insufficiently understood. We evaluated, whether 31 novel biomarkers could help to predict the risk of incident diabetes. METHODS AND FINDINGS: The biomarkers were evaluated primarily in the FINRISK97 cohort (n = 7,827; 417 cases of clinically incident diabetes during the follow-up). The findings were replicated in the Health 2000 cohort (n = 4,977; 179 cases of clinically incident diabetes during the follow-up). We used Cox proportional hazards models to calculate the relative risk of diabetes, after adjusting for the classic risk factors, separately for each biomarker. Next, we assessed the discriminatory ability of single biomarkers using receiver operating characteristic curves and C-statistics, integrated discrimination improvement (IDI) and net reclassification improvement (NRI). Finally, we derived a biomarker score in the FINRISK97 cohort and validated it in the Health 2000 cohort. A score consisting of adiponectin, apolipoprotein B, C-reactive protein and ferritin almost doubled the relative risk of diabetes in the validation cohort (HR per one standard deviation increase 1.88, p = 2.8 e-5). It also improved discrimination of the model (IDI = 0.0149, p<0.0001) and reclassification of diabetes risk (NRI = 11.8%, p = 0.006). Gender-specific analyses suggested that the best score differed between men and women. Among men, the best results were obtained with the score of four biomarkers: adiponectin, apolipoprotein B, ferritin and interleukin-1 receptor antagonist, which gave an NRI of 25.4% (p<0.0001). Among women, the best score included adiponectin, apolipoprotein B, C-reactive protein and insulin. It gave an NRI of 13.6% (p = 0.041). CONCLUSIONS: We identified novel biomarkers that were associated with the risk of clinically incident diabetes over and above the classic risk factors. This gives new insights into the pathogenesis of diabetes and may help with targeting prevention and treatment. Public Library of Science 2010-04-09 /pmc/articles/PMC2852424/ /pubmed/20396381 http://dx.doi.org/10.1371/journal.pone.0010100 Text en Salomaa et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Salomaa, Veikko
Havulinna, Aki
Saarela, Olli
Zeller, Tanja
Jousilahti, Pekka
Jula, Antti
Muenzel, Thomas
Aromaa, Arpo
Evans, Alun
Kuulasmaa, Kari
Blankenberg, Stefan
Thirty-One Novel Biomarkers as Predictors for Clinically Incident Diabetes
title Thirty-One Novel Biomarkers as Predictors for Clinically Incident Diabetes
title_full Thirty-One Novel Biomarkers as Predictors for Clinically Incident Diabetes
title_fullStr Thirty-One Novel Biomarkers as Predictors for Clinically Incident Diabetes
title_full_unstemmed Thirty-One Novel Biomarkers as Predictors for Clinically Incident Diabetes
title_short Thirty-One Novel Biomarkers as Predictors for Clinically Incident Diabetes
title_sort thirty-one novel biomarkers as predictors for clinically incident diabetes
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2852424/
https://www.ncbi.nlm.nih.gov/pubmed/20396381
http://dx.doi.org/10.1371/journal.pone.0010100
work_keys_str_mv AT salomaaveikko thirtyonenovelbiomarkersaspredictorsforclinicallyincidentdiabetes
AT havulinnaaki thirtyonenovelbiomarkersaspredictorsforclinicallyincidentdiabetes
AT saarelaolli thirtyonenovelbiomarkersaspredictorsforclinicallyincidentdiabetes
AT zellertanja thirtyonenovelbiomarkersaspredictorsforclinicallyincidentdiabetes
AT jousilahtipekka thirtyonenovelbiomarkersaspredictorsforclinicallyincidentdiabetes
AT julaantti thirtyonenovelbiomarkersaspredictorsforclinicallyincidentdiabetes
AT muenzelthomas thirtyonenovelbiomarkersaspredictorsforclinicallyincidentdiabetes
AT aromaaarpo thirtyonenovelbiomarkersaspredictorsforclinicallyincidentdiabetes
AT evansalun thirtyonenovelbiomarkersaspredictorsforclinicallyincidentdiabetes
AT kuulasmaakari thirtyonenovelbiomarkersaspredictorsforclinicallyincidentdiabetes
AT blankenbergstefan thirtyonenovelbiomarkersaspredictorsforclinicallyincidentdiabetes